These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 17297453)

  • 21. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
    Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE
    Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance.
    Louie MC; McClellan A; Siewit C; Kawabata L
    Mol Cancer Res; 2010 Mar; 8(3):343-52. PubMed ID: 20215421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
    Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
    Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.
    Davies MP; Barraclough DL; Stewart C; Joyce KA; Eccles RM; Barraclough R; Rudland PS; Sibson DR
    Int J Cancer; 2008 Jul; 123(1):85-8. PubMed ID: 18386815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
    Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.
    Tozlu-Kara S; Roux V; Andrieu C; Vendrell J; Vacher S; Lazar V; Spyratos F; Tubiana-Hulin M; Cohen P; Dessen P; Lidereau R; Bièche I
    J Mol Endocrinol; 2007 Oct; 39(4):305-18. PubMed ID: 17909269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.
    Juncker-Jensen A; Lykkesfeldt AE; Worm J; Ralfkiaer U; Espelund U; Jepsen JS
    Growth Horm IGF Res; 2006 Aug; 16(4):224-39. PubMed ID: 16893667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
    Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
    Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
    Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
    Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology.
    Near RI; Zhang Y; Makkinje A; Vanden Borre P; Lerner A
    J Cell Physiol; 2007 Sep; 212(3):655-65. PubMed ID: 17427198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ; Raney S
    Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
    Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
    Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A20 inhibits human salivary adenoid cystic carcinoma cells invasion via blocking nuclear factor-kappaB activation.
    Zhang B; Guan CC; Chen WT; Zhang P; Yan M; Shi JH; Qin CL; Yang Q
    Chin Med J (Engl); 2007 Oct; 120(20):1830-5. PubMed ID: 18028781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.
    Lü M; Ding K; Zhang G; Yin M; Yao G; Tian H; Lian J; Liu L; Liang M; Zhu T; Sun F
    Sci Rep; 2015 Mar; 5():8735. PubMed ID: 25736597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells.
    Kilker RL; Hartl MW; Rutherford TM; Planas-Silva MD
    J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):63-71. PubMed ID: 15544931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer.
    Chan CM; Lykkesfeldt AE; Parker MG; Dowsett M
    Clin Cancer Res; 1999 Nov; 5(11):3460-7. PubMed ID: 10589759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling.
    Badia E; Duchesne MJ; Semlali A; Fuentes M; Giamarchi C; Richard-Foy H; Nicolas JC; Pons M
    Cancer Res; 2000 Aug; 60(15):4130-8. PubMed ID: 10945620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.